Dr. Saar I. Gill, MD

Dr. Gill practices at Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania.

Dr. Gill's NPI, 1306126644, was assigned on August 18, 2011. Dr. Gill holds Pennsylvania license MD443294.

Dr. Gill's primary practice is Hospital of the University of Pennsylvania, at 3400 Spruce St, Philadelphia, PA 19104 in Philadelphia County. The practice phone is (215) 662-6289.

Dr. Gill's primary practice is Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, part of University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Gill to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gill practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Gill's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Gill is licensed in Pennsylvania.

CMS data shows 134 Medicare services from Dr. Gill across 3 procedure codes in 2024, for 58 Medicare patients. Medicare paid $10,335 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 58 Medicare patients who saw Dr. Gill in 2024. The largest group is 65 to 74, with 35 patients. 75% of them have high blood pressure, and 69% have high cholesterol. Their average risk score is 3.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gill's median patient age at 64, with 39% women.

In 2024, Dr. Gill wrote 95 Medicare Part D claims for 14 patients. 66% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $209,848 in total drug cost. In 2023, CMS named 50 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Gill for performance year 2024, reported as part of a group. Dr. Gill accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 116 papers to Dr. Gill, published from 2011 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Immunotherapy, Adoptive, T-Lymphocytes and Hematopoietic Stem Cell Transplantation. Dr. Gill has published most often in Leuk Lymphoma. Dr. Gill's most frequent co-authors are Noelle Virginia Frey, MD, Carl June, MD and David L. Porter, MD.

Dmand AI links Dr. Gill to 1 clinical trial. Conditions studied include Fever and Agranulocytosis.

CMS Open Payments shows 29 general payments to Dr. Gill from 11 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 77% of the total. Kite Pharma, Inc. paid the most, $7,669.